Anand Vihar railway station to house isolation coaches | WeForNews | Latest News, Blogs Anand Vihar railway station to house isolation coaches – WeForNews | Latest News, Blogs
Connect with us

Disaster

Anand Vihar railway station to house isolation coaches

Published

on

Anand Vihar Terminal Main Building

New Delhi, June 14 : The Indian Railways has decided to shift all the five train services from Anand Vihar railway station to old Delhi railway station to house the isolation ward coaches for the novel coronavirus (Covid-19) patients, officials said on Sunday.

According to a Northern Railway official, the services of five trains that started on June 1 are being shifted to Old Delhi railway station from Anand Vihar railway station.

The services of five trains will be shifted to Old Delhi railway station from Tuesday.

He said, the decision has been taken as the railways has planned to use the Anand Vihar railway station for isolation ward coaches to treat Covid-19 patients.

The coaches are equipped will all the medical facilities required for the treatment of Covid patients.

The decision came hours after Union Home Minister Amit Shah on Sunday said that 500 railway isolation coaches will be deployed in Delhi for Covid-19 patients.

The Railways has converted 5,231 coaches into isolation ward for Covid-19 patients.

Earlier in the day, the National transporter said it has deployed 204 of such coaches in four states so far, with 54 coaches being deployed at Delhi”s Shakurbasti railway station maintenance depot.

Railway officials said that the capacity in the capital will be scaled up to 500 coaches in the coming days for 8,000 Covid-19 patients.

Disaster

COVID-19 pandemic “once in a century”, but still “in our hands”: WHO

“I’m not saying there is no solution now. Whatever happens in the next few months or years, I also believe that it’s in our hands,” he said.

Published

on

By

Tedros Adhanom Ghebreyesus WHO

Geneva, Aug 4 : The chief of the World Health Organization (WHO) said that the COVID-19 pandemic is “a once-in-a-century health crisis,” but it is still “in our hands.”

WHO Director-General Tedros Adhanom Ghebreyesus said at a virtual press conference on Monday that the world has never seen anything like this pandemic for decades, and its effects might last for decades more, Xinhua news agency reported.

“Since we started probably recording, this is the first ever coronavirus-caused pandemic which has two dangerous combinations: it moves fast, and at the same time it’s a killer,” the WHO chief explained.

However, he noted, although the crisis is very severe, there are still solutions and hopes.

“I’m not saying there is no solution now. Whatever happens in the next few months or years, I also believe that it’s in our hands,” he said.

“Since the outbreak started, many countries have shown that it can be controlled, or serious transmission can be suppressed,” Tedros said, adding that he has mentioned many such countries in the past, including Spain, Italy, China and South Korea.

Continue Reading

Disaster

One person is dying of COVID-19 every seven minutes in Iran: state TV

The report said that Iran’s official coronavirus figures were based only on the number of deaths in hospitals and those who had already tested positive for the coronavirus.

Published

on

Iran Covid Case

DUBAI : One person is dying from COVID-19 every seven minutes in Iran, state television said on Monday, as the Health Ministry reported 215 new deaths from the disease and state media warned of a lack of proper social distancing.

Health Ministry spokesman Sima Sadat Lari was quoted by the state TV as saying the 215 deaths in the past 24 hours took the combined death toll to 17,405 in Iran, and the number of confirmed cases rose by 2,598 to 312,035.

State television showed several Iranians in a busy Tehran street without wearing face masks or social distancing.

Some experts have doubted the accuracy of Iran’s official coronavirus tolls. A report by the Iranian parliament’s research centre in April suggested that the coronavirus tolls might be almost twice as many as those announced by the health ministry.

The report said that Iran’s official coronavirus figures were based only on the number of deaths in hospitals and those who had already tested positive for the coronavirus.

British broadcaster BBC reported on Monday that, based on data from an anonymous source, the number of deaths in Iran might be three times higher than officially reported. Iranian health authorities denied the report and said there had been no covebakingr-up.

With COVID-19 deaths surging since restrictions were eased in mid-April, Iranian authorities have said measures to curb the spread of COVID-19 will be reimposed if health regulations are not observed. Since last month, wearing face masks in public places and covered spaces has been mandatory.

Iran’s National Coronavirus Combat Taskforce was expected to announce later on Monday whether nationwide university entrance examinations, with over 1 million participants, will take place in August. Many Iranians have called on social media for the examinations to be postponed.

Continue Reading

Disaster

Jubilant Life Sciences launches remdesivir for injection

‘JUBI-R’ will require to be administered intravenously in a hospital setting under the supervision of a medical practitioner.

Published

on

remdesivir injection

New Delhi, Aug 3 : Jubilant Life Sciences Ltd on Monday announced that its subsidiary, Jubilant Generics, has launched remdesivir for injection, under the brand name ‘JUBI-R’, in the Indian market at a price of Rs 4,700 per vial of 100 mg.

The company said it will make the drug available to over 1,000 hospitals providing Covid-19 treatment in India through its distribution network.

In May this year, Jubilant entered into a non-exclusive Licensing Agreement with Gilead Sciences that granted it the right to register, manufacture and sell Gilead’s investigational drug remdesivir in 127 countries including India.

Remdesivir is an antiviral drug that has received Emergency Use Authorisation (EUA) by the US FDA for treatment of suspected or laboratory confirmed Covid-19 in adults and children hospitalised with severe disease.

On July 20, Jubilant received approval from the Drug Controller General of India (DCGI) to manufacture and market the investigational antiviral drug remdesivir (‘JUBI-R’) for 100 mg/vial (lyophilized injection) for restricted emergency use in India for the treatment of severe Covid-19.

“The company’s ability to launch this product in such short timelines highlights our R&D and manufacturing capabilities and our continued commitment to provide leading healthcare solutions,” Shyam Bhartia, Chairman & Managing Director and Hari Bhartia, Co-Chairman, Jubilant Pharma Ltd, said in a statement.

“Through the Jubilant Bhartia Foundation, we will distribute the drug on compassionate basis to save precious lives of people through unique programmes.”

‘JUBI-R’ will require to be administered intravenously in a hospital setting under the supervision of a medical practitioner.

Continue Reading
Advertisement

Most Popular

Corona Virus (COVID-19) Live Data

COVID-19 affects different people in different ways. Most infected people will develop mild to moderate illness and recover without hospitalization.